Randomized non-inferiority study: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection
21 Jan, 2021 | 01:01h | UTCLong-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study – The Lancet (link to abstract – $ for full-text)
Commentary (thread – click for more)
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with #HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study: https://t.co/4SdfnRRCje
— The Lancet (@TheLancet) December 21, 2020